Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.65 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.59 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.59 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ACACB | O00763 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16199815 | 0.91 | S1PR1 (0.59) | RARBTP53TSHRPLA2G4BS1PR1 | |
| SCHEMBL12243191 | 0.91 | S1PR1 (0.59) | RARBTP53TSHRPLA2G4BS1PR1 | |
| SCHEMBL6132663 | 0.91 | RARB (0.55) | RARBTP53TSHRPLA2G4BS1PR1 | |
| SCHEMBL6132571 | 0.91 | RARB (0.55) | RARBTP53TSHRPLA2G4BS1PR1 | |
| SCHEMBL12294471 | 0.89 | S1PR1 (0.58) | RARBTP53TSHRPLA2G4BS1PR1 | |
| SCHEMBL13926721 | 0.89 | S1PR1 (0.69) | RARBTP53S1PR1S1PR3NPC1 | |
| SCHEMBL7340382 | 0.88 | S1PR1 (0.57) | RARBTP53TSHRPLA2G4BS1PR1 | |
| SCHEMBL61028 | 0.87 | NPC1 (0.60) | RARBTP53TSHRPLA2G4BS1PR1 | |
| SCHEMBL12243347 | 0.87 | S1PR1 (0.56) | RARBTP53TSHRPLA2G4BS1PR1 | |
| SCHEMBL14072336 | 0.86 | NPC1 (0.61) | RARBPLA2G4BS1PR1S1PR3PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| EP-2350119-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | Merlion Pharmaceuticals Pte Ltd. (SG) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
| EP-0788511-B1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-6265536-B1 | MICROBIOCIDE AND FUNGICIDE WHICH IS INHIBITOR OF BETA-1,3-GLUCAN SYNTHASE; TREATMENT OF PNEUMOCYSTIS CARINII INFECTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| US-6107458-A | FUNGICIDE WHICH IS BETA-1,3-GLYCAN SYNTHASE INHIBITOR; FOR PROPHYLAXIS AND TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS LIKE PNEUMONIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-22 | — | — | US | disclosed |
| EP-0788511-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996011210-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | RARB 2792/4885TP53 3875/4885TSHR 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.